Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Non-Hodgkin 6Recurrence 5Lymphoma, Mantle-Cell 5Lymphoma 5Lymphoma, B-Cell 3Dendritic Cell Sarcoma, Interdigitating 2Neoplasms 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Cytokine Release Syndrome 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Rituximab 25Lenalidomide 21Cyclophosphamide 20Prednisone 14obinutuzumab 12Vincristine 12Doxorubicin 11Magnetic Resonance Spectroscopy 10Bendamustine Hydrochloride 9Specimen Handling 8ibrutinib 7Biopsy 7fludarabine 6pembrolizumab 5fludarabine phosphate 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5zanubrutinib 4venetoclax 4tazemetostat 4Whole-Body Irradiation 4R-CHOP protocol 4Prednisolone 3Mycophenolic Acid 3Etoposide 3Cyclosporine 3tisagenlecleucel 2polatuzumab vedotin 2orelabrutinib 2loncastuximab tesirine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × glofitamab × 90 days × Clear all
NCT05783596 2026-03-16

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡